Commercial-stage, biopharmaceutical company HUTCHMED (China) Limited (Nasdaq:HCM)(AIM:HCM)(HKEX:13) and Innovent Biologics, Inc. (HKEX:1801), a biopharmaceutical company, on Tuesday jointly announce New Drug Application, (NDA) acceptance in China for fruquintinib combination with sintilimab in advanced endometrial cancer, granted Priority Review after Breakthrough Therapy designation in July 2023.
This marks the first regulatory filing for fruquintinib in combination with a leading immune checkpoint inhibitor. The NDA targets patients with advanced endometrial cancer who are not eligible for curative surgery or radiation.
The submission is based on data from FRUSICA-1, a Phase II study evaluating the combination's efficacy and safety. Primary endpoints include objective response rate, with secondary endpoints covering various clinical and pharmacokinetic assessments. Breakthrough Therapy designation was granted due to the combination's potential in addressing an unmet medical need with significant clinical advantages. Fruquintinib, a selective oral VEGFR inhibitor, shows promise in inhibiting tumor angiogenesis with enhanced selectivity and sustained target inhibition, potentially expanding its utility in combination therapies.
Transgene teams up with ProBioGen for individualised cancer vaccines
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
HUTCHMED receives milestone payment from Takeda for FRUZAQLA sales
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024